Operating Income (Loss) in USD of 2seventy bio, Inc. from 2019 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
2seventy bio, Inc. quarterly/annual Operating Income (Loss) history and change rate from 2019 to Q1 2025.
  • 2seventy bio, Inc. Operating Income (Loss) for the quarter ending 31 Mar 2025 was -$2,520,000.000, a 95.1% increase year-over-year.
  • 2seventy bio, Inc. Operating Income (Loss) for the twelve months ending 31 Mar 2025 was -$66,796,000.000, a 71.8% increase year-over-year.
  • 2seventy bio, Inc. annual Operating Income (Loss) for 2024 was -$115,430,000.000, a 51.4% increase from 2023.
  • 2seventy bio, Inc. annual Operating Income (Loss) for 2023 was -$237,608,000.000, a 9.7% increase from 2022.
  • 2seventy bio, Inc. annual Operating Income (Loss) for 2022 was -$263,140,000.000, a 16.2% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

2seventy bio, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$66,796,000 -$2,520,000 +$48,634,000 +95.1% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025
Q4 2024 -$115,430,000 -$23,266,000 +$36,670,000 +61.2% 01 Oct 2024 31 Dec 2024 10-K 25 Mar 2025
Q3 2024 -$152,100,000 -$13,941,000 +$64,027,000 +82.1% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2024
Q2 2024 -$216,127,000 -$27,069,000 +$20,922,000 +43.6% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024
Q1 2024 -$237,049,000 -$51,154,000 +$559,000 +1.1% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025
Q4 2023 -$237,608,000 -$59,936,000 -$32,724,000 -1.2% 01 Oct 2023 31 Dec 2023 10-K 25 Mar 2025
Q3 2023 -$204,884,000 -$77,968,000 -$9,600,000 -14% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024
Q2 2023 -$195,284,000 -$47,991,000 +$28,981,000 +37.7% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 -$224,265,000 -$51,713,000 +$38,875,000 +42.9% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024
Q4 2022 -$263,140,000 -$27,212,000 +$41,157,000 +60.2% 01 Oct 2022 31 Dec 2022 10-K 07 Mar 2024
Q3 2022 -$304,297,000 -$68,368,000 -$3,130,000 -4.8% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 -$301,167,000 -$76,972,000 +$10,999,000 +12.5% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 -$312,166,000 -$90,588,000 +$1,782,000 +1.9% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023
Q4 2021 -$313,948,000 -$68,369,000 01 Oct 2021 31 Dec 2021 10-K 07 Mar 2024
Q3 2021 -$65,238,000 +$11,176,000 +14.6% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022
Q2 2021 -$87,971,000 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022
Q1 2021 -$92,370,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022
Q3 2020 -$76,414,000 01 Jul 2020 30 Sep 2020 10-Q 01 Dec 2021

2seventy bio, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$115,430,000 +$122,178,000 +51.4% 01 Jan 2024 31 Dec 2024 10-K 25 Mar 2025
2023 -$237,608,000 +$25,532,000 +9.7% 01 Jan 2023 31 Dec 2023 10-K 25 Mar 2025
2022 -$263,140,000 +$50,808,000 +16.2% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024
2021 -$313,948,000 -$175,778,000 -1.3% 01 Jan 2021 31 Dec 2021 10-K 07 Mar 2024
2020 -$138,170,000 +$202,550,000 +59.4% 01 Jan 2020 31 Dec 2020 10-K 16 Mar 2023
2019 -$340,720,000 01 Jan 2019 31 Dec 2019 10-K 22 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.